肝细胞癌患者经化疗栓塞或放射栓塞治疗后移植结局的对比研究
172例肝细胞癌患者在接受经动脉化疗栓塞(79例)或钇-90放射栓塞(93例)后桥接或降期至原位肝移植,移植后中位随访26.1个月,两组复发率、无复发生存期和总生存期均相似;降期至UNOS T2或以下者无复发生存期有改善趋势。
要点
- Y90组等待肝移植时间较长(6.5 vs 4.8个月,p=0.02),但移植后结局与TACE组相似。
- 移植后肿瘤复发率TACE组8%(6/79)与Y90组9%(8/93)相近,无复发生存期和总生存期差异无统计学意义。
- 降期至UNOS T2或以下者无复发生存期风险比为0.6(CI: 0.33-1.1),未达统计学显著。
核心结论
- 尽管Y90组等待肝移植时间较长,TACE或Y90桥接/降期后移植的肝细胞癌患者移植后结局相似,降期患者无复发生存期有改善趋势但未达统计学显著。
研究设计与样本
- 研究纳入172例接受经动脉局部治疗(Y90组93例,TACE组79例)后行原位肝移植的肝细胞癌患者,分析治疗前和移植前临床、影像和实验室特征,并进行单因素、多因素和分层分析,移植后通过影像随访评估复发。
诊断标准与关键数值
- 移植后肿瘤复发:TACE组6/79(8%),Y90组8/93(9%)。
- 复发时间:TACE组26.6个月(CI: 7.0-49.5),Y90组15.9个月(CI: 7.8-46.8),p=0.48。
- 无复发生存期:Y90组79个月 vs TACE组77个月,p=0.84。
- 总生存期:Y90组100个月时存活57%;TACE组84.2个月,p=0.57。
- 降期至UNOS T2或以下者无复发生存期风险比:降期患者0.6(CI: 0.33-1.1),未降期患者1.7(CI: 0.9-3.1),p=0.13。
临床应用与阅片要点
- 原研究未给出临床应用推荐;结果提示TACE或Y90桥接/降期后移植的肝细胞癌患者移植后结局相似,降期至UNOS T2或以下者无复发生存期有改善趋势(风险比0.6,CI: 0.33-1.1,未达统计学显著)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To analyze long-term outcomes in patients bridged/downstaged to orthotopic liver transplantation (OLT) by transarterial chemoembolization (TACE) or yttrium-90 radioembolization (Y90) for hepatocellular carcinoma (HCC).
METHODS: 172 HCC patients who underwent OLT after being treated with transarterial liver-directed therapies (LDTs) (Y90: 93; TACE: 79) were identified. Pre-LDT and pre-OLT clinical/imaging/laboratory characteristics including United Network for Organ Sharing (UNOS) staging and alpha-fetoprotein values (AFP) were tabulated. Post-OLT HCC recurrence was assessed by imaging follow-up per standard of care. Recurrence-free (RFS) and overall survival (OS) were calculated. Uni/multivariate and sub-stratification analyses were performed.
RESULTS: Time-to-OLT was longer in the Y90 group (Y90: 6.5 months; TACE: 4.8 months; p=0.02). With a median post-OLT follow-up of 26.1 months (IQR: 11.1-49.7), tumor recurrence was found in 6/79 (8%) TACE and 8/93 (9%) Y90 patients. Time-to-recurrence was 26.6 (CI: 7.0-49.5) and 15.9 months (CI: 7.8-46.8) for TACE and Y90, respectively (p=0.48). RFS (Y90: 79 months; TACE: 77 months; p=0.84) and OS (Y90: 57% alive at 100 months; TACE: 84.2 months; p=0.57) were similar. 54/155 patients (Y90: 29; TACE: 25) were downstaged to UNOS T2 or less. RFS hazard ratios for patients downstaged to ≤T2 versus those that were not were 0.6 (CI: 0.33-1.1) and 1.7 (CI: 0.9-3.1) respectively (p=0.13). 17/155 patients (Y90: 8; TACE: 9) that were >T2 were downstaged to UNOS T2 or less (within transplant criteria). Distribution (unilobar/bilobar), AFP, and pre-transplant UNOS stage affected RFS on univariate analyses.
CONCLUSION: Despite longer time-to-OLT for Y90 patients, post-OLT outcomes were similar between patients bridged or downstaged by TACE or Y90. A trend towards improved RFS for downstaged patients was identified.
引用
- Gabr A, Abouchaleh N, Ali R, et al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. Eur J Radiol. 2017. PMID: 28668402. doi:10.1016/j.ejrad.2017.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。